Recent performance snapshot

Twist Bioscience (TWST) stock has been on investors’ radar after a sharp move in recent months, with the share price closing at $67.77 and recent returns showing a mix of short term pressure and longer term strength.

Recent pressure, with a 1-day share price return of 3.27% and 7-day share price return of 6.30%, comes after a strong run that includes a 30-day share price return of 20.57%, a 90-day share price return of 57.53%, and a 1-year total shareholder return of 92.80%. This signals momentum that has cooled slightly in the very near term.

If Twist Bioscience has caught your attention, this is also a good time to look beyond a single stock and scan the wider biotech and healthcare AI space using the 39 healthcare AI stocks

With Twist Bioscience growing revenue and narrowing its loss, yet trading slightly above the average analyst price target, you need to ask whether the recent surge still leaves room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 5.3% Overvalued

At a last close of $67.77 versus a narrative fair value of $64.38, the most followed story around Twist Bioscience sees the stock pricing in a premium that leans on ambitious earnings and growth assumptions.

In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 44.3x on those 2029 earnings, up from -55.4x today. This future PE is greater than the current PE for the US Biotechs industry at 16.4x.

Want to understand why this narrative leans on such a rich future earnings multiple, plus faster revenue growth and higher margins than today? The full story connects those moving parts into a single fair value anchor that could shift quickly if any of the inputs change.

Result: Fair Value of $64.38 (OVERVALUED)

However, this story can change quickly if customer concentration in NGS softens revenue, or if ongoing losses force fresh funding that dilutes existing shareholders.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

The mix of optimism and caution around Twist Bioscience is clear, so consider acting while sentiment is still forming and review the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Twist Bioscience has sharpened your focus, do not stop here. Expanding your watchlist with fresh stock ideas can reveal opportunities you might otherwise miss.

• Target potential mispricing by scanning 47 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying businesses.
• Strengthen your income stream by reviewing 9 dividend fortresses that aim to pair higher yields with resilient business models.
• Protect your capital by focusing on 63 resilient stocks with low risk scores that score well on financial strength and downside resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.